Clinical Trial of an IL-23 Inhibitor for Immune Activation in Clinical Trial of an IL-23 Inhibitor for Immune Activation in People With Schizophrenia

Conditions: Schizophrenia; Schizo Affective Disorder; Healthy

Interventions: Drug: Placebo; Drug: IL-23

Sponsors: University of Maryland, Baltimore

Not yet recruiting